Health Technology Assessment Guidelines and Recommendations Across European Union Countries and the United Kingdom in Rare Disease and Paediatric Populations.

WHY IT MATTERS

If your country updates its health technology assessment rules, it could affect how quickly new rare disease treatments get approved and whether your insurance will cover them.

European countries are updating their rules for deciding whether new medicines work well and are worth the cost, especially for rare diseases and children. Because rare diseases affect few people and there's less testing data available, countries are making special adjustments to their evaluation methods. This study looked at how 28 European countries and the UK are handling these evaluations differently.

Health Technology Assessment Guidelines and Recommendations Across European Union Countries and the United Kingdom in Rare Disease and Paediatric Populations. Abstract: Due to limited clinical data, high uncertainty, and outcome variability, assessing therapies for paediatric and rare disease populations poses specific challenges, often requiring adjustments to standard health technology assessment (HTA) frameworks. This study examines how national HTA guidelines and recommendations across Europe reflect these demands, identifying methodological adaptations and country-specific disparities. HTA organisations across the 27 EU Member States and the UK were identified via INAHTA, EUnetHTA, and ISPOR reference listings. Publicly available documents were screened, and 29 relevant national guidelines were selected. A structured document analysis was performed using a predefined coding framework. Key terms were systematically searched, and content was categorise Authors: Bártová et al. Journal: Applied health economics and health policy MeSH: Humans, Technology Assessment, Biomedical, Rare Diseases, United Kingdom, Child, European Union, Practice Guidelines as Topic, Cost-Benefit Analysis, Guidelines as Topic, Pediatrics